Status:
UNKNOWN
Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis
Lead Sponsor:
Hvidovre University Hospital
Conditions:
Liver Cirrhosis
Portal Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The study´s purpose is to investigate the effect of beta blockade or aldosterone antagonist therapy on oxygenation, peripheral and cardiac hemodynamics and humoral systems, in patients with liver cirr...
Detailed Description
Cardio-pulmonal complications to patients with liver cirrhosis and portal hypertension determine the patients' prognosis. Most patients have hemodynamical changes in circulation with increased cardiac...
Eligibility Criteria
Inclusion
- Liver cirrhosis
- Clinical indication for treatment with betablocker or aldosterone antagonist
- Must not have been treated earlier with betablocker or aldosterone antagonist
- Must have been alcohol abstinent for more than 4 weeks
Exclusion
- Gastrointestinal bleeding in the last 2 weeks
- Encephalopathy \> grade 1
- Acute medical conditions
- Malignant disease
- Pregnancy
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00332904
Start Date
August 1 2006
End Date
December 1 2010
Last Update
June 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Physiology and Nuclear Medicine, and Department for Gastrointestinal Medicine, Hvidovre Hospital
Hvidovre, Denmark, 2650